G Irwin Gordon Sells 3,000 Shares of Heska Corp. (HSKA) Stock
Heska Corp. (NASDAQ:HSKA) Director G Irwin Gordon sold 3,000 shares of the company’s stock in a transaction on Tuesday, November 29th. The stock was sold at an average price of $66.11, for a total transaction of $198,330.00. Following the transaction, the director now owns 17,596 shares of the company’s stock, valued at approximately $1,163,271.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Heska Corp. (NASDAQ:HSKA) opened at 66.11 on Thursday. The company has a market cap of $456.03 million, a price-to-earnings ratio of 52.93 and a beta of 0.74. Heska Corp. has a 12-month low of $26.25 and a 12-month high of $69.80. The stock has a 50 day moving average of $58.16 and a 200 day moving average of $48.46.
Heska Corp. (NASDAQ:HSKA) last posted its earnings results on Tuesday, November 1st. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.20. The firm earned $33.40 million during the quarter, compared to analyst estimates of $31.36 million. Heska Corp. had a net margin of 7.55% and a return on equity of 10.46%. Heska Corp.’s revenue for the quarter was up 19.3% on a year-over-year basis. Equities research analysts predict that Heska Corp. will post $1.32 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “G Irwin Gordon Sells 3,000 Shares of Heska Corp. (HSKA) Stock” was first posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2016/12/01/g-irwin-gordon-sells-3000-shares-of-heska-corp-hska-stock.html.
A number of brokerages recently weighed in on HSKA. Benchmark Co. began coverage on shares of Heska Corp. in a research report on Tuesday. They set a “buy” rating and a $78.00 target price for the company. Sidoti lowered shares of Heska Corp. from a “buy” rating to a “neutral” rating and set a $71.00 target price for the company. in a research report on Monday. B. Riley reiterated a “neutral” rating and set a $55.50 price objective on shares of Heska Corp. in a research report on Monday, November 7th. Finally, Zacks Investment Research upgraded shares of Heska Corp. from a “hold” rating to a “buy” rating and set a $63.00 price objective for the company in a research report on Wednesday, November 2nd. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $66.88.
Several institutional investors have recently bought and sold shares of HSKA. Prudential Financial Inc. raised its position in Heska Corp. by 229.6% in the first quarter. Prudential Financial Inc. now owns 22,250 shares of the company’s stock valued at $634,000 after buying an additional 15,500 shares during the period. Acadian Asset Management LLC raised its position in Heska Corp. by 21.5% in the second quarter. Acadian Asset Management LLC now owns 102,804 shares of the company’s stock valued at $3,821,000 after buying an additional 18,211 shares during the period. Adams Diversified Equity Fund Inc. purchased a new position in Heska Corp. during the second quarter valued at $279,000. Pembroke Management LTD purchased a new position in Heska Corp. during the second quarter valued at $5,096,000. Finally, Bank of Montreal Can purchased a new position in Heska Corp. during the second quarter valued at $128,000. 72.70% of the stock is owned by hedge funds and other institutional investors.
About Heska Corp.
Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company focuses on the canine and feline companion animal health markets. Its segments include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.
Receive News & Stock Ratings for Heska Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp. and related stocks with our FREE daily email newsletter.